# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Diana, Princess of Wales (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML028-SYN-TD
- Date: 1990-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Castleford, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week review: potassium and ECG on fluoxetine 60 mg, CBT-E progress, mood, and safety. **S**

## History of present illness

Ms. Spencer returns four weeks after the consultation. She has had seven CBT-E sessions, twice a week, and keeps her self-monitoring record every day. Binge eating with vomiting has fallen to about three times a week, and she eats breakfast and lunch on four or five days a week. She took fluoxetine 20 mg for a week, 40 mg for a week, and has taken 60 mg each morning for two weeks. She had mild nausea in the first week, which passed; she sleeps well and has had no agitation or restlessness. The nurse's phone check ten days after the start found no concerns. She has taken potassium chloride twice daily. She has not booked a dental examination. Her mood is better and she has had no thoughts of suicide or self-harm. **S**

| Element | Detail |
|---|---|
| Binge eating and vomiting | About three times a week, from seven |
| CBT-E | Seven sessions, twice weekly |
| Fluoxetine | 60 mg each morning for two weeks; nausea in the first week only |
| Mood | Better; PHQ-9 9; item 9 scored 0 |
| Dental examination | Not yet booked |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No palpitations or fainting |
| Gastrointestinal | Positive | Vomiting after binges about three times a week; nausea from fluoxetine has passed |
| Ears, nose, mouth, and throat | Positive | Teeth sensitive to cold |
| Psychiatric | Negative | Mood better; no agitation; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Fluoxetine 60 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 61.6 kg; BMI 19.4 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 3.9 mmol/L; Chloride: 101 mmol/L; Bicarbonate (total CO2): 26 mmol/L; Creatinine: 0.78 mg/dL; eGFR: 106 mL/min/1.73 m²; Magnesium: 2 mg/dL; QTc (ECG): 441 ms; PHQ-9: 9. All results are synthetic.

## Change since baseline

- Sodium: 137 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 3.1 mmol/L (low) at baseline, 3.9 mmol/L at this visit **S**
- Chloride: 94 mmol/L (low) at baseline, 101 mmol/L at this visit **S**
- Bicarbonate (total CO2): 32 mmol/L (high) at baseline, 26 mmol/L at this visit **S**
- Creatinine: 0.84 mg/dL at baseline, 0.78 mg/dL at this visit **S**
- eGFR: 97 mL/min/1.73 m² at baseline, 106 mL/min/1.73 m² at this visit **S**
- Magnesium: 1.8 mg/dL at baseline, 2 mg/dL at this visit **S**
- QTc (ECG): 452 ms at baseline, 441 ms at this visit **S**
- PHQ-9: 14 at baseline, 9 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 61.6 kg, BMI 19.4; lying blood pressure 106/66 and pulse 70, standing 104/68 and pulse 82 after three minutes |
| Head and neck | Parotid glands a little smaller; enamel erosion unchanged |
| Psychiatric | Brighter; organized; no psychomotor agitation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypokalemia from vomiting** (E87.6). Resolved: potassium 3.9 mmol/L, the second normal value, with chloride 101 and bicarbonate 26 mmol/L and magnesium 2.0 mg/dL, as the vomiting has fallen to about three times a week. **S**
   - Stop potassium chloride.
   - Electrolytes at each medical visit while any vomiting continues; call for palpitations, cramps, or weakness.
2. **Bulimia nervosa, severe** (F50.23). Good early response to CBT-E and fluoxetine: about three episodes a week, from ten at intake. ECG two weeks after reaching fluoxetine 60 mg: sinus rhythm 70/min, QTc 441 ms, down from 452 ms as potassium has recovered. The dental examination advised at intake has not been booked. **S**
   - Continue CBT-E; weekly sessions from next week.
   - Continue fluoxetine 60 mg each morning.
   - Book a dental examination; no brushing for an hour after vomiting and a fluoride mouthwash meanwhile.
3. **Major depressive disorder, recurrent, moderate** (F33.1). PHQ-9 9, from 14. No agitation on fluoxetine. Safety reviewed: no thoughts of suicide or self-harm; the safety plan is current. **S**
   - PHQ-9 at the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Binge-eating and vomiting frequency (her self-monitoring record) | Every visit | Completed today | About three episodes a week, from seven at the last visit and ten at intake |
| Survey | Eating Disorder Examination Questionnaire (EDE-Q) global score | Baseline, mid-treatment, and end of treatment | Up to date | Global score 3.9 at intake; mid-treatment questionnaire with the therapist at about twelve weeks |
| Examination | Weight and BMI | Every visit, and weekly in CBT-E sessions | Completed today | 61.6 kg, BMI 19.4; weighed weekly in CBT-E |
| Examination | Lying and standing pulse and blood pressure | Every visit while purging continues | Completed today | Lying 106/66, pulse 70; standing 104/68, pulse 82 (rise 12) |
| Laboratory | Potassium, chloride, bicarbonate, and creatinine | Weekly until potassium is normal twice, then at each medical visit while purging continues | Completed today | Potassium 3.9 mmol/L, the second normal value; sodium 140, chloride 101, bicarbonate 26 mmol/L; creatinine 0.78 mg/dL, eGFR 106 |
| Laboratory | Second potassium check one week after the first normal value | Weekly until potassium is normal twice | Deferred | Not drawn: the plan at the one-week visit set the next electrolyte check for this visit, four weeks later, instead of one week later. She stayed on potassium chloride throughout, had no symptoms, and potassium today is 3.9 mmol/L, so no harm resulted. Corrective action: while potassium is low or newly normal, electrolytes are drawn weekly at the laboratory between visits |
| Laboratory | Magnesium and phosphate | Baseline, and again while potassium is low | Completed today | Magnesium 2.0 mg/dL; phosphate normal at intake and not repeated |
| Laboratory | ECG with QTc | Baseline with purging or low potassium; after a QT-relevant medicine reaches its full dose while potassium has been low | Completed today | QTc 441 ms, from 452 ms, two weeks after reaching fluoxetine 60 mg |
| Examination | Parotid and dental examination; dental protection | Every visit; a dental examination soon after diagnosis and regular dental reviews while vomiting continues | Deferred | The dental examination advised at intake has not happened: she put off booking it from embarrassment. Erosion unchanged and no tooth pain, so no harm is evident yet. Corrective action: the clinic gave her a list of dentists who see people with eating disorders, and the therapist will ask about it at the next session |
| Medication safety | Oral potassium supplement | While potassium is low or vomiting is frequent | Completed today | Stopped today after a second normal potassium |
| Medication safety | Fluoxetine dose, adherence, and side effects (nausea, sleep, agitation, sexual effects, suicidal thoughts) | At the start, one to two weeks after starting or a dose change, then every visit | Completed today | 60 mg for two weeks; nausea in the first week only; no agitation or suicidal thoughts; the nurse phone check at ten days found no concerns |
| Self-management | CBT-E attendance and progress | Up to 20 sessions over 20 weeks, twice weekly for the first four weeks | Completed today | Seven sessions; self-monitoring record kept daily; weekly from next week |
| Self-management | Regular eating and dietitian review | Every visit | Completed today | Breakfast and lunch on four or five days a week |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, then periodically | Completed today | PHQ-9 9, item 9 scored 0 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan current; the 988 Suicide & Crisis Lifeline in her phone |
| Examination | Level-of-care review against thresholds for urgent or inpatient care | Every visit | Completed today | Outpatient care remains safe |

## Goal progress

- No binge eating or vomiting for at least four weeks by the end of 20 weeks of CBT-E. In progress; target 1990-07-13. **S**
- Potassium at least 3.5 mmol/L on two checks within four weeks. Outcome by 1990-03-16: Potassium 3.6 and 3.9 mmol/L; supplement stopped. **S**
- Regular eating (three meals and two or three snacks) on most days by three months. In progress; target 1990-05-11. **S**
- PHQ-9 score below 5 by the end of treatment. In progress; target 1990-07-13. **S**
- EDE-Q global score below 2.0 by the end of treatment. In progress; target 1990-07-13. **S**

## Medication changes

- Stopped: Potassium chloride 20 mEq extended-release oral tablet, one tablet by mouth twice daily with food **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders, Fourth Edition (2023), American Psychiatric Association (American Journal of Psychiatry 2023;180(2):167-171)
- Eating disorders: recognition and treatment (NICE guideline NG69) (2017, updated 2020), National Institute for Health and Care Excellence
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- CBT-E weekly. Book a dental examination. Preventive visit in four weeks. Three-month review in eight weeks with electrolytes, the EDE-Q, and the PHQ-9. **S**
- Next scheduled visit 1990-04-13: periodic adult preventive visit. **S**
